-
Je něco špatně v tomto záznamu ?
A simulation of loading doses for vancomycin continuous infusion regimens in intensive care
M. Šíma, K. Hronová, J. Hartinger, O. Slanař,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, pozorovací studie
- MeSH
- intravenózní infuze MeSH
- lidé středního věku MeSH
- lidé MeSH
- obezita MeSH
- péče o pacienty v kritickém stavu metody MeSH
- počítačová simulace MeSH
- poločas MeSH
- retrospektivní studie MeSH
- senioři MeSH
- tělesná hmotnost MeSH
- vankomycin aplikace a dávkování krev terapeutické užití MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND: Delayed achievement of target vancomycin serum concentrations may adversely affect clinical outcomes. The objective of this retrospective study was to compare the prediction accuracy of different body weight descriptors for volume of distribution and to propose an optimal loading dose (LD) for continuous infusion regimens in adults. METHODS: Pharmacokinetic variables were computed using one-compartmental analysis. Simulated LDs of vancomycin were evaluated for each patient. RESULTS: Volume of distribution, clearance, and half-life median values (interquartile range) for vancomycin in the study population (n = 30) were 0.45 (0.39-0.61) L.kg-1, 0.026 (0.015-0.040) L.h-1.kg-1, and 10.3 (7.7-21.3) h, respectively. The observed volume of distribution was better predicted by total body weight (TBW) than by the ideal body weight or the adjusted body weight. CONCLUSIONS: An LD of 10.7 mg per kg TBW was optimal in our study population. Using this LD, 17.9% of simulated vancomycin serum levels were just below the therapeutic range, only 10.7% concentrations exceeded the target range and no concentration was toxic. The use of a LD would lead to reduced median time to reach target concentrations from 17 to 1 h.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025023
- 003
- CZ-PrNML
- 005
- 20240522100420.0
- 007
- ta
- 008
- 180709s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/23744235.2017.1328741 $2 doi
- 035 __
- $a (PubMed)28504034
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine , Charles University and General University Hospital in Prague , Prague , Czech Republic.
- 245 12
- $a A simulation of loading doses for vancomycin continuous infusion regimens in intensive care / $c M. Šíma, K. Hronová, J. Hartinger, O. Slanař,
- 520 9_
- $a BACKGROUND: Delayed achievement of target vancomycin serum concentrations may adversely affect clinical outcomes. The objective of this retrospective study was to compare the prediction accuracy of different body weight descriptors for volume of distribution and to propose an optimal loading dose (LD) for continuous infusion regimens in adults. METHODS: Pharmacokinetic variables were computed using one-compartmental analysis. Simulated LDs of vancomycin were evaluated for each patient. RESULTS: Volume of distribution, clearance, and half-life median values (interquartile range) for vancomycin in the study population (n = 30) were 0.45 (0.39-0.61) L.kg-1, 0.026 (0.015-0.040) L.h-1.kg-1, and 10.3 (7.7-21.3) h, respectively. The observed volume of distribution was better predicted by total body weight (TBW) than by the ideal body weight or the adjusted body weight. CONCLUSIONS: An LD of 10.7 mg per kg TBW was optimal in our study population. Using this LD, 17.9% of simulated vancomycin serum levels were just below the therapeutic range, only 10.7% concentrations exceeded the target range and no concentration was toxic. The use of a LD would lead to reduced median time to reach target concentrations from 17 to 1 h.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a tělesná hmotnost $7 D001835
- 650 _2
- $a počítačová simulace $7 D003198
- 650 _2
- $a péče o pacienty v kritickém stavu $x metody $7 D003422
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a poločas $7 D006207
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intravenózní infuze $7 D007262
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a obezita $7 D009765
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a vankomycin $x aplikace a dávkování $x krev $x terapeutické užití $7 D014640
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Hronová, Karolína $u Department of Pharmacology, First Faculty of Medicine , Charles University and General University Hospital in Prague , Prague , Czech Republic.
- 700 1_
- $a Hartinger, Jan $u Department of Pharmacology, First Faculty of Medicine , Charles University and General University Hospital in Prague , Prague , Czech Republic. $7 xx0224709
- 700 1_
- $a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine , Charles University and General University Hospital in Prague , Prague , Czech Republic.
- 773 0_
- $w MED00191578 $t Infectious diseases $x 2374-4243 $g Roč. 49, č. 9 (2017), s. 674-679
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28504034 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20240522100416 $b ABA008
- 999 __
- $a ok $b bmc $g 1317154 $s 1021944
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 49 $c 9 $d 674-679 $e 20170514 $i 2374-4243 $m Infectious diseases $n Infect Dis (Lond) $x MED00191578
- LZP __
- $a Pubmed-20180709